From the Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium; Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; Division of Academic Rheumatology, University of Nottingham; National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research (NIHR), Leeds Biomedical Research Centre, Leeds, UK; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, Sorbonne Université, INSERM, Saint-Antoine Hospital AP-HP, DHU i2B, Paris, France; Department of Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
R. Wittoek, MD, PhD, Department of Rheumatology, Ghent University Hospital, Ghent University; F.P. Kroon, MD, Department of Rheumatology, Leiden University Medical Center; B. Kundakci, PT, MSc, Division of Academic Rheumatology, University of Nottingham; A. Abhishek, MD, MRCP, PhD, Division of Academic Rheumatology, University of Nottingham, and National Institute for Health Research, Nottingham Biomedical Research Centre; I.K. Haugen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; F. Berenbaum, MD, PhD, Department of Rheumatology, Sorbonne Université, INSERM, Saint-Antoine hospital AP-HP, DHU i2B; P.G. Conaghan MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research, Leeds Biomedical Research Centre; M.L. Ishimori, MD, Department of Medicine, Division of Rheumatology, Cedars-Sinai Medical Center; W. Smeets, Patient Representative, Department of Rheumatology, Leiden University Medical Center; D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; M. Kloppenburg, MD, PhD, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Center.
J Rheumatol. 2019 Sep;46(9):1183-1187. doi: 10.3899/jrheum.181003. Epub 2019 Jan 15.
To evaluate hand osteoarthritis tools for core instrument set development.
For OMERACT 2018, a systematic literature review and advances in instrument validation were presented.
Visual analog and numerical rating scales were considered valuable for pain and patient's global assessment, despite heterogeneous phrasing and missing psychometric evidence for some aspects. The Modified Intermittent and Constant Osteoarthritis Pain scale was lacking evidence. The Michigan Hand Outcomes Questionnaire had advantages above other pain/function questionnaires. The Hand Mobility in Scleroderma scale was valid, although responsiveness was questioned. Potential joint activity instruments were evaluated.
The development of the core instrument set is progressing, and a research agenda was also developed.
评估手部骨关节炎工具,以开发核心仪器集。
在 OMERACT 2018 年,系统的文献回顾和仪器验证的进展情况。
视觉模拟和数字评分量表被认为对疼痛和患者整体评估有价值,尽管在某些方面存在不一致的措辞和缺乏心理测量证据。改良间歇性和持续性骨关节炎疼痛量表缺乏证据。密歇根手功能问卷在疼痛/功能问卷方面优于其他问卷。硬皮病手部活动度量表具有有效性,但反应度受到质疑。潜在的关节活动度评估工具也进行了评估。
核心仪器集的开发正在进行中,同时也制定了研究议程。